SCHEMBL18477157

SCHEMBL18477157

CC(C)N1CCN(C(=S)N/N=C2/CCNc3cccnc32)CC1

nearest known ligand 0.37

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 4/20 0.37
LMNA P02545 3/20 0.36
KDM4E B2RXH2 4/20 0.33
ALDH1A1 P00352 3/20 0.33
POLB P06746 1/20 0.33
HRH3 Q9Y5N1 3/20 0.32
HKDC1 Q2TB90 1/20 0.32
MITF O75030 1/20 0.32
CTSL P07711 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
MAPT P10636 1/20 0.32
HRH1 P35367 1/20 0.31
HTT P42858 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18477152 0.88 HSP90AA1 (0.39) HSP90AA1LMNAKDM4EPOLBHRH3
SCHEMBL18477154 0.86 PTAFR (0.40) HSP90AA1HKDC1MITFHRH1
SCHEMBL18477166 0.86 HSP90AA1 (0.38) HSP90AA1KDM4EPOLBHKDC1CTSL
SCHEMBL18477165 0.85 LMNA (0.37) HSP90AA1LMNAKDM4EALDH1A1POLB
SCHEMBL18479516 0.85 KDM4E (0.47) LMNAKDM4EALDH1A1MEN1KMT2A
SCHEMBL18479522 0.84 ATM (0.38) LMNAALDH1A1MEN1KMT2AMAPT
SCHEMBL18477144 0.84 HSP90AA1 (0.38) HSP90AA1LMNAKDM4EALDH1A1POLB
SCHEMBL18477155 0.84 ALDH1A1 (0.41) HSP90AA1KDM4EALDH1A1CTSLMEN1
SCHEMBL18477147 0.84 MEN1 (0.38) HSP90AA1LMNAALDH1A1POLBHKDC1
SCHEMBL18477158 0.83 HSP90AA1 (0.45) HSP90AA1LMNAKDM4EALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10392397-B2 Heterocyclic thiosemicarbazone derivatives and their therapeutical applications NANTBIO, INC. (US) 2019-08-27 US disclosed
US-20180208603-A1 HETEROCYCLIC THIOSEMICARBAZONE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS NANT HOLDINGS IP, LLC 2018-07-26 US disclosed
US-20180208603-A1 HETEROCYCLIC THIOSEMICARBAZONE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS NANT HOLDINGS IP, LLC 2018-07-26 US disclosed
WO-2017024315-A1 HETEROCYCLIC THIOSEMICARBAZONE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS NANT HOLDINGS IP, LLC (US) 2017-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10392397-B2 Heterocyclic thiosemicarbazone derivatives and their therapeutical applications TPMT, MKI67, TST HSP90AA1 158/4885LMNA 4312/4885KDM4E 2904/4885
US-20180208603-A1 HETEROCYCLIC THIOSEMICARBAZONE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS TPMT, MKI67, TST HSP90AA1 158/4885LMNA 4312/4885KDM4E 2904/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.